REFERENCES
- Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115–126.
- Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32–40.
- Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, CoIlen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coro-nary artery disease. Circulation. 1998;98:1487–1494.
- Hulthe J, Fagerberg B. Circulating oxidized LDL is associ-ated with subclinical atherosclerosis development and in-flammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol. 2002;22:1162–1167.
- Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 200121: 844–848.
- Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J. Oxi-dized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clini-cally healthy men. J Intern Med. 2004;256:413–420.
- Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospho-lipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57.
- Petit JM, Duong M, Duvillard L, et al. LDL-receptors ex-pression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy. Eur J Clin Invest. 2002;32:354–359.
- Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
- Mary-Krause M, Cotte L, Simon A, Partisani M, Costaglinola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486.
- Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.
- Duong M, Cottin Y, Piroth L, et al. Exercise stress testing for detection of silent myocardial ischemia in human immu-nodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2002;34:523–528.
- Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726–735.
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004;27:1487–1495.
- Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. Arterioscler Thromb Vasc Biol. 2000;20:E63–E67.
- Millar JS, Maugeais C, Ikewaki K, et al. Complete defi-ciency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol. 2005;25:560–565.
- Umpleby AM, Das S, Stolinski M, et al. Low density lipo-protein apolipoprotein B metabolism in treatment-naïve HIV patients and patients on antiretroviral therapy. Antivir Ther. 2005;10:663–670.
- Weinbrenner T, Schröder H, Escurriol V, et al. Circulating oxidized LDL is associated with increased waist circumfer-ence independent of body mass index in men and women. Am J Clin Nutr. 2006;83:30–35.
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Associa-tion. Circulation. 2003;107:499–511.
- Lau B, Sharrett R, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease pro-gression. Arch Intern Med. 2006;166:64–70.
- Henry K, Kitch D, Dube M, et al. C-reactive protein levels over time and cardiovascular risk in HIV-infected individu-als suppressed on an indinavir-based regimen: AIDS Clini-cal Trials Group 5056s. AIDS. 2004;18:2434–2437.
- Hsue P, Lo J, Franklin A, et al. C-reactive protein levels in patients with HIV: a marker of cardiovascular risk or chronic infection? Poster presented at the 12th Confer-ence on Retroviruses and Opportunistic Infections; Febru-ary 2005; Boston. Poster 864.
- Inoue T, Hayashi M, Takayanagi K, Morooka S. Lipid-lowering therapy with fluvastatin inhibits oxidative modifi-cation of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Ath-erosclerosis. 2002;160:369–376.